Skip to main content
Podcast: Treating Parkinson's 'Off' Episodes

How MJFF “De-Risks” PD Drug Development Pipeline

One key pillar of The Michael J. Fox Foundation’s research strategy is a focus on “de-risking" potential treatments for Parkinson’s disease. This episode of our award-winning “Parkinson’s Science POV” series explains how providing funding and resources to lower the risk associated with developing new therapies leads to a more robust pipeline of treatments.  

If you’d rather listen on the go, subscribe to our Michael J. Fox Foundation Parkinson's Podcast on iTunes or through any podcast app on your smartphone or tablet. If you enjoyed what you heard, share it with a friend or leave a review on iTunes. It helps listeners like you find and support our mission.  

Join Maggie Kuhl, vice president of research engagement at The Michael J. Fox Foundation (MJFF), as she leads a discussion about some recent successes of MJFF’s de-risking strategy with our expert panelists:  

  • Brian Fiske, PhD, MJFF co-chief science officer

  • Mark Frasier, PhD, MJFF co-chief science officer

  • Shalini Padmanabhan, PhD, vice president, discovery and translational research 

View a transcript of this podcast.  

Join a study today to help speed progress toward better treatments and a cure for Parkinson’s disease. To search for studies in your area, visit Fox Trial Finder.  

Whether you have Parkinson’s or not, you can help move research forward. Join the study that’s changing everything. 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.